SIS System (Version 5.1.0)
Surgical Information Sciences, Inc. • Radiology • 03/31/2021
Device Purpose
The SIS System version 5.1.0 is a software application utilizing deep learning convolutional neural networks, trained on 7T MRI data, to generate patient-specific 3D anatomical models of brain structures like the STN and GPe/GPi from clinical MR images. Its purpose is to aid medical professionals in viewing, image processing, image fusion, and intraoperative functional planning, including the localization and orientation detection of implanted leads from CT scans.
Summary
The SIS System (version 5.1.0) is a software application designed for medical professionals, including surgeons, neurologists, and radiologists, to assist in the viewing, presentation, and documentation of medical imaging. It incorporates modules for image processing, image fusion, and intraoperative functional planning, with its 3D output being compatible with stereotactic image-guided surgery systems for further processing and visualization. The system specifically aids in the visualization of the subthalamic nuclei (STN) and globus pallidus externa and interna (GPe and GPi), supplementing standard clinical methods by providing additional adjunctive information for planning stereotactic surgical procedures and lead output. The system's technology is based on machine learning and image processing, utilizing pre-trained deep learning convolutional neural network (CNN) models to create patient-specific 3D anatomical models of these brain structures from a patient's clinical MR images. These CNN models were trained using ultra-high resolution 7T Magnetic Resonance images as ground truth. A key update in version 5.1.0 includes an algorithm based on these deep learning models, the addition of GPe/GPi as visualization targets, and a new functionality to determine the orientation of directional leads segmented from post-operative CT images. Performance data demonstrated that visualization accuracy for STN and GPi/GPe met acceptance criteria, MRI to CT registration accuracy was maintained, and lead segmentation from CT images was validated. The electrode orientation detection was accurate within ±30° in 91% of trusted detections, with over 90% of all presented orientations meeting this accuracy.
AI Regulatory Concerns
Powered by
Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.
Keywords
Device Metadata
Relevant Clinical Questions
- Q1. How does the performance of the deep learning CNN models for segmenting GPe/GPi compare to existing gold-standard manual segmentation techniques in terms of accuracy and time efficiency?; What specific architectural features of the convolutional neural network models were optimized for brain image segmentation, and how do they contribute to improved visualization of STN and GPe/GPi?; What is the clinical impact of the ±30° accuracy range for directional lead orientation detection on postoperative programming and patient outcomes?; How does the system handle variability in MR image quality and acquisition parameters across different clinical sites when applying the pre-trained deep learning models?; Beyond STN and GPe/GPi, what other brain structures could this deep learning methodology be applied to for enhanced visualization and surgical planning?
Risk Classification
ESL AnalysisFDA Class II via 510(k) pathway; IEC 62304 Class B (software safety classification); Authorized before §524B enforcement
Learn how Parasoft automates IEC 62304 compliance testing →Cybersecurity Evidence
Powered by SBOMator™Based on AI-generated device summaries, not the full FDA submission. Items not detected here may still be present in the complete submission package.
Supply Chain BOM Evidence
Based on the CycloneDX / OWASP ECMA-424 xBOM ecosystem. Detection is from the AI-generated summary.
Analysis:
• Analysis is based on the AI-generated device summary, not the full FDA submission package. Click "Analyze Full FDA PDF" below to scan the actual submission document.
• Evidence of ML-BOM, SaaSBOM detected in AI-generated device summary.
• This device was authorized before §524B took effect. Cybersecurity evidence requirements were less prescriptive at the time.
• Postmarket cybersecurity monitoring plan not clearly documented in AI-generated device summary.
• Not detected in AI-generated device summary: SBOM, HBOM, CBOM, VDR/VEX, OBOM. These may be present in the full FDA submission.
Preparing a similar submission?
ESL takes complete ownership of your software evidence work - SBOM & CVE remediation with SBOMator™, static analysis & unit testing with Parasoft, traceability, and full IEC 62304 lifecycle support.
Assess Your Readiness →Or contact ESL directly